Value20202021202220232024TTMSelling/general/admin expenses————39.31 M—Research & development53.01 M32.81 M27.19 M25.35 M34.81 M—Operating income-36.5 M-19.1 M-17.84 M-25.42 M-29.84 M—Non-Operating Income, Total——————Interest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses——————Unusual income/expense——————Pretax income99.63 M91.59 M82.1 M88.15 M101.81 M—Equity in earnings——————Taxes819 K239 K212 K191 K330 K—Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations98.81 M91.35 M81.89 M87.96 M102.14 M—Discontinued operations——————Net income98.81 M91.35 M81.89 M87.96 M102.14 M—Dilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders——————Basic earnings per share (Basic EPS)——————Diluted earnings per share (Diluted EPS)——————Average basic shares outstanding——————Diluted shares outstanding——————EBITDA——————EBIT——————Cost of revenue————5.13 M—Other cost of goods sold——————Depreciation & amortization (cash flow)4.26 M4.38 M4.11 M4.67 M2.46 M—
Mesoblast Limited - American Depositary Shares
Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004.